RNS Number : 0438Q
N4 Pharma PLC
08 July 2025

8 July 2025

N4 Pharma plc

("N4 Pharma" or the "Company")

Directorate Change

N4 Pharma plc (AIM: N4P),the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, is pleased to announce the appointment of Edward Wardleas a Non-Executive Director of the Company with immediate effect.

Edward is joining the Board as a representative of Northern Standard Limited, which is the Company's largest shareholder. Edward brings board-level experience of strategy, corporate governance and business development. Having founded and led multiple businesses, he is currently an investment adviser with Tracarta Limited and Northern Standard Limited, focusing on critical industries and cutting-edge technologies, as well as a Senior Business Development Executive at Ironveld plc. He joined the Board of AIM-listed TheraCryf plc, the clinical stage drug development company focusing on neuropsychiatry and oncology, as a Non-Executive Director in May 2025.

Nigel Theobald, Chief Executive Officer of N4 Pharma, said:

"We are delighted to welcome Ed to the Board of N4 Pharma, representing our largest shareholder. His experience in strategy, corporate governance, business development, and his background in innovative technologies will be invaluable as N4 Pharma develops its Nuvec® platform and continues to build out its data packages to secure licensing opportunities."

Edward Wardle commented:

"Northern Standard sees a future where N4 Pharma's Nuvec® platform shifts the paradigm of drug delivery by enabling the evolution of advanced RNA therapies; where time-consuming, in-clinic injections become something as small as a pill. We believe N4 Pharma has the technology, IP, and world-class team necessary to deliver this future, and are honoured to support them as they do."

- Ends -

The following information is disclosed pursuant to Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies in relation to Edward James Norman Wardle, aged 34:

Current Directorships/Partnerships	**Past Directorships/Partnerships (within 5 years)**
TheraCryf PLC	Otherworld Manchester Limited
The Hammer Organization Limited	

Otherworld Piccadilly Limited The Dream Corporation Limited* Otherworld Dublin Limited	Otherworld Birmingham Limited

*Per Schedule Two paragraph (g)(v) of the AIM Rules for Companies - The Dream Corporation Limited is currently undergoing creditors' voluntary liquidation, with KRE Corporate Recovery appointed as licensed insolvency practitioners on 22 July 2024. It is currently anticipated there will not be surplus funds to pay a distribution to any class of creditor.

Edward Wardle is a 49% shareholder in Northern Standard Limited, which is interested in 150,000,000 ordinary shares in the Company. Northern Standard Limited is a 51% owned subsidiary of Tracarta Limited, a company in which John Wardle, Edward Wardle's father, has a beneficial interest.

In addition, Mr Wardle personally holds 18,750,000 warrants to subscribe for new ordinary shares in the Company exercisable at 0.4p per share which expire on 4 April 2030.

For more information please contact:

N4 Pharma plc
Nigel Theobald, CEO
Luke Cairns, Executive Director
Via N4 Pharma Investor Hub:investors.n4pharma.com

Submit your questions directly to the management team via the N4 Pharma Investor Hub
https://investors.n4pharma.com/link/0rJNYr

SP Angel CorporateFinance LLP
Nominated Adviser and Joint Broker
Matthew Johnson/Jen Clarke (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
Tel: +44 (0)20 3470 0470

Turner Pope Investments (TPI) Limited
Joint Broker
Andy Thacker
James Pope
Tel: +44 (0)20 3657 0050

Northstar Communications Limited
Investor Relations
Sarah Hollins
Tel: +44 (0)113 730 3896

About N4 Pharma

N4 Pharma is a pre-clinical biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases.

RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.

N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners.

N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for IBD which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform.

For further information on the Company visitwww.n4pharma.comor sign up athttps://investors.n4pharma.com/auth/signup.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAUBVSRVBUBRAR